Stock Code: 688276 Stock Abbreviation: Baike Bio Announcement No.: 2022-016
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.
Important content reminder:
● Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as the “Company”) stock trading within 2 consecutive trading days (May 23, 2022, May 20, 2022) The cumulative deviation of the closing price increase reached 30%. The relevant provisions of the Trading Rules of the Shanghai Stock Exchange, the Special Regulations on the Trading of Stocks on the Sci-tech Innovation Board of the Shanghai Stock Exchange, and the Detailed Rules for the Real-time Monitoring of Abnormal Stock Transactions on the Sci-tech Innovation Board of the Shanghai Stock Exchange (for Trial Implementation) belong to abnormal fluctuations in stock transactions.
● After the company’s self-inspection and a letter to the controlling shareholder and actual controller, as of May 23, 2022, there is no material information that should be disclosed but has not been disclosed.
● The company has noticed that some media have published reports on the occurrence of monkeypox virus infection cases in many countries and published reports on listed companies with monkeypox virus-related products or technical reserves, which involve the company. The company’s varicella vaccine cannot prevent monkeypox, and the company currently has no products related to the prevention of monkeypox virus.
1. Specific circumstances of abnormal fluctuations in stock trading
The company’s stock trading within 2 consecutive trading days (May 23, 2022, May 20, 2022) The deviation of the closing price increase has reached 30%. According to the “Shanghai Stock Exchange Trading Rules”, “Shanghai Stock Exchange Science and Technology Innovation The relevant provisions of the Special Regulations on Stock Trading on the Shanghai Stock Exchange and the Detailed Rules for the Real-time Monitoring of Abnormal Stock Transactions on the Shanghai Stock Exchange’s Science and Technology Innovation Board (for Trial Implementation) belong to abnormal fluctuations in stock transactions.
2. Relevant situations that the company has paid attention to and verified
According to the relevant regulations of the Shanghai Stock Exchange, the company has conducted necessary verifications on relevant issues. The description is as follows:
(1) Production and operation
After the company’s self-examination, the company’s current production and operation activities are all normal. The market environment and industry policies have not undergone major adjustments, production costs and sales have not fluctuated significantly, the internal production and operation order is normal, no major contracts have been signed or under negotiation recently, and no new projects have been invested in industrial transformation and upgrading.
(2) Major events
After the company’s self-inspection and the company’s controlling shareholder sent a letter to confirm, as of May 23, 2022, the company, its controlling shareholder and actual controller did not have any material information that should be disclosed but not disclosed, including but not limited to planned mergers and acquisitions. , share issuance, debt restructuring, business restructuring, asset divestiture and asset injection and other major events.
(3) Media reports, market rumors, and hot concepts
The company has noticed that some media have published reports on the occurrence of monkeypox virus infection cases in many countries and published reports on listed companies with monkeypox virus-related products or technical reserves, which involve the company.
On May 20, 2022, the company responded to the relevant questions through the “SSE E Interactive” platform as follows: Monkeypox virus and smallpox virus belong to the genus Orthopoxvirus of the Poxviridae family, and are a viral zoonotic disease. It is transmitted from animals to people through direct and close contact, and can also be transmitted from person to person. The main routes of infection include blood and body fluids. The infectivity of monkeypox is far less than that of smallpox virus. The varicella-zoster virus belongs to the herpesviridae family, and has no animal reservoir host. Humans are the only natural host and are transmitted through the respiratory tract. The company’s varicella vaccine cannot prevent monkeypox, and the company has no products related to the prevention of monkeypox virus.
In addition, the company has not found any media reports or market rumors that may have a greater impact on the company’s stock trading price, nor has it found other major events that may have a greater impact on the company’s stock price. All company information is subject to the information published on the website of the Shanghai Stock Exchange (www.sse.com.cn) and designated media.
(IV) Other stock price sensitive information
After the company’s self-examination and verification, the company’s directors, supervisors, senior managers, controlling shareholders, and actual controllers did not buy or sell the company’s stocks during the period of abnormal fluctuations in the stock transaction.
3. Statement of the Board of Directors and Commitments of Related Parties
The board of directors of the company confirms that, except for the matters disclosed in accordance with relevant regulations, the company has no matters that should be disclosed according to the “Shanghai Stock Exchange’s Listing Rules for Stocks on the Science and Technology Innovation Board” and other relevant regulations but has not been disclosed or plans related to such matters. The Board of Directors has not been informed of any information that should have been disclosed according to the “Shanghai Stock Exchange’s Rules for the Listing of Stocks on the Science and Technology Innovation Board” and other relevant regulations, but has not been disclosed, and may have a significant impact on the trading price of the company’s shares and derivatives. “
4. Relevant risk warning
1. The company will truthfully, accurately, timely, completely and fairly disclose material information that may affect the company’s stock price to investors in accordance with the requirements of the Company Law, the Securities Law and other relevant laws and regulations for investors to make decisions. investment judgment. Restricted by objective conditions, the company cannot grasp the reasons and trends of stock market changes. The company reminds investors to pay attention to stock price fluctuations and the risks that may be involved in the stock market in the future.
2. The company has noticed that the research reports released by some securities companies have forecast the company’s future operating income, profit level, earnings per share, stock price and other indicators. The above forecast data only represents the independent judgment of third-party research institutions, without the company Confirmation, the relevant information is subject to the company announcement.
3. The company solemnly reminds investors that “China Securities Journal”, “Shanghai Securities News”, “Securities Daily” and “Securities Times” are the company’s designated newspapers for information disclosure, and the website of the Shanghai Stock Exchange (http://www.sse .com.cn) is the designated information disclosure website for the company. All company information is subject to the information published in the above designated media. Investors are requested to make rational analysis and pay attention to investment risks.
5. Attachments to online announcements
Reply to “Inquiry Letter on Abnormal Stock Trading Fluctuations of Changchun Baike Biotechnology Co., Ltd.”.
Special announcement.
Changchun Baike Biotechnology Co., Ltd. Board of Directors
May 24, 2022
<!–
–>